Cart
sales@molnova.com
RV1088
CAS No. 1229606-73-8
RV1088( RV-1088 | RV 1088 )
Catalog No. M10903 CAS No. 1229606-73-8
RV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRV1088
-
NoteResearch use only, not for human use.
-
Brief DescriptionRV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually.
-
DescriptionRV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually, dose-dependently reduces TNF-α levels in LPS-activated macrophages with IC50 of 0.63 nM; also reduces IL-6 production effectively with IC50 of 1.66 nM, RV1088 is significantly more effective at inhibiting IL-6 and IL-8 production by monocytes and RA synovial fibroblasts compared with Humira; TNF-α, IL-6 and IL-8 synthesis in RA synovial membrane cells with low nM IC50s.
-
In Vitro——
-
In Vivo——
-
SynonymsRV-1088 | RV 1088
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1229606-73-8
-
Formula Weight578.673
-
Molecular FormulaC33H34N6O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyridinyl]-2-methoxyacetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
CC-99677
CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
-
RWJ 67657
A potent, selective, orally active p38 MAPK inhibitor that inhibits the production of TNF-α and IL-1β by LPS-stimulated human PBMCs with IC50 of 3 and 11 nM, respectively.
